View More Recent Stories

Nov 3, 2022 08:00AM Aadi Bioscience to Present at Upcoming Investor Conferences
Nov 2, 2022 08:00AM Aadi Bioscience to Report Third Quarter 2022 Results and Corporate Update
Oct 27, 2022 08:00AM Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium
Oct 12, 2022 08:02AM Aadi Bioscience (AADI) Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus
Oct 12, 2022 08:01AM Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium
Oct 12, 2022 08:00AM Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C
Sep 1, 2022 08:00AM Aadi Bioscience Announces Participation in Upcoming September Investor Conferences
Aug 10, 2022 08:00AM Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update
Jul 28, 2022 08:30AM Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update
Jun 23, 2022 08:00AM Aadi Bioscience (AADI) to Join Russell 2000 and Russell 3000 Indexes
Jun 23, 2022 08:00AM Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes
Jun 1, 2022 08:00AM Aadi Bioscience to Present at the Jefferies Global Healthcare Conference
May 31, 2022 08:00AM Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications
May 26, 2022 05:10PM Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting
View More Recent Stories